Ademi LLP is investigating Fulcrum's recent merger with Slate Medicines for potential breaches of fiduciary duty and other legal violations. The merger terms give Fulcrum shareholders only 5% ownership in the combined company, with Slate shareholders holding 95%. Fulcrum is expected to contribute $20.3 million in net cash and pay a $270 million dividend to its shareholders before the merger closes. Concerns include substantial benefits to Fulcrum insiders and restrictive terms limiting competing bids. The investigation focuses on whether Fulcrum's board acted in shareholders' best interests.
BitFuFu Inc. reported a Q2 2026 earnings per share of -$0.02, missing estimates and showing a 100% earnings surprise. Revenue fell 62.9% year-over-year to $42.8 million, driven by a 27.5% drop in Bitcoin price and lower demand for cloud mining, resul...
Sensus Healthcare reported a sharp decline in Q2 revenue to $2.3 million, down from $7.3 million last year, due to delayed financing for its SRT-100 medical devices. The company has severed ties with the problematic bank causing the delays and expect...
Duos Technologies Group (DUOT) has sold its rail technology subsidiary to focus on the AI data center market, securing over $500 million in five-year hosting service contracts with Axe Compute Inc. The company reported Q2 earnings per share of $0.66 ...
Shopify reported strong Q2 2026 earnings, surpassing analyst expectations thanks to significant growth in AI-driven commerce. AI-driven traffic and orders to Shopify stores tripled year-over-year, boosting confidence in the company's AI innovation. S...
Freightos Limited reported Q2 results surpassing expectations with an EPS of -$0.03 versus -$0.05 expected and record revenue of $7.7 million, driven by a 19% increase in core platform revenue. The company narrowed its adjusted EBITDA loss to $2 mill...
